Publicacións en colaboración con investigadores/as de Hospital Severo Ochoa (19)

2024

  1. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

    Blood, Vol. 144, Núm. 6, pp. 646-656

2023

  1. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

2021

  1. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

  2. Management of acquired hemophilia A: results from the Spanish registry

    Blood Advances, Vol. 5, Núm. 19, pp. 3821-3829

2020

  1. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

    Experimental Hematology and Oncology

  2. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

    Thrombosis and Haemostasis, Vol. 120, Núm. 3, pp. 437-448

2019

  1. Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients

    Blood Coagulation and Fibrinolysis, Vol. 30, Núm. 3, pp. 127-132

  2. Unraveling the effect of silent, intronic and missense mutations on VWF splicing: Contribution of next generation sequencing in the study of mRNA

    Haematologica, Vol. 104, Núm. 3, pp. 587-598

2018

  1. Role of multimeric analysis of von willebrand factor (VWF) in von willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Further psychometric validation of the GAH scale: Responsiveness and effect size

    Journal of Geriatric Oncology, Vol. 8, Núm. 3, pp. 211-215

  2. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

2016

  1. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia

    British Journal of Haematology, Vol. 174, Núm. 5, pp. 700-710

  2. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

2015

  1. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211

2011

  1. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab

    Expert Review of Hematology, Vol. 4, Núm. 1, pp. 9-16

2008

  1. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study

    Haematologica, Vol. 93, Núm. 12, pp. 1829-1836

1999

  1. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: The main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-α. Results of the CML89 trial of the Spanish collaborative group on interferon-α2a and CML

    Haematologica, Vol. 84, Núm. 11, pp. 978-987

1997

  1. Trasplante autólogo de células stem periféricas en pacientes con leucemia mieloide crónica tras movilización con altas dosis de hidroxiurea

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 17-23